U.S. markets open in 8 minutes
  • S&P Futures

    4,253.25
    -27.75 (-0.65%)
     
  • Dow Futures

    33,514.00
    -204.00 (-0.61%)
     
  • Nasdaq Futures

    13,518.75
    -59.00 (-0.43%)
     
  • Russell 2000 Futures

    1,999.60
    -17.30 (-0.86%)
     
  • Crude Oil

    87.14
    -4.95 (-5.38%)
     
  • Gold

    1,794.40
    -21.10 (-1.16%)
     
  • Silver

    20.07
    -0.63 (-3.03%)
     
  • EUR/USD

    1.0208
    -0.0049 (-0.48%)
     
  • 10-Yr Bond

    2.7930
    -0.0560 (-1.97%)
     
  • Vix

    21.09
    +0.89 (+4.41%)
     
  • GBP/USD

    1.2097
    -0.0042 (-0.35%)
     
  • USD/JPY

    132.6800
    -0.8000 (-0.60%)
     
  • BTC-USD

    24,109.96
    -370.10 (-1.51%)
     
  • CMC Crypto 200

    572.30
    +1.02 (+0.18%)
     
  • FTSE 100

    7,472.33
    -28.56 (-0.38%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Aligos Therapeutics
Aligos Therapeutics

SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company’s second quarter 2022 financial results on Thursday, August 4, 2022 after the close of the U.S. financial markets.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2022 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
+1 315 879 8192
ajobe@lifescicomms.com

Investor Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com